600222 Stock Overview
Engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Henan Taloph Pharmaceutical Stock Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.44 |
| 52 Week High | CN¥6.33 |
| 52 Week Low | CN¥3.75 |
| Beta | 0.63 |
| 1 Month Change | 3.23% |
| 3 Month Change | 25.93% |
| 1 Year Change | -11.11% |
| 3 Year Change | -32.51% |
| 5 Year Change | 26.51% |
| Change since IPO | -35.04% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) Revenues Yet
Sep 27
Henan Taloph Pharmaceutical StockLtd (SHSE:600222) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 06Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE:600222) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Mar 08Shareholder Returns
| 600222 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.2% | -4.3% | -3.5% |
| 1Y | -11.1% | -3.4% | 10.9% |
Return vs Industry: 600222 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 600222 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 600222 volatility | |
|---|---|
| 600222 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600222 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600222's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,353 | Jingliang Li | www.taloph.com |
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Danshen oral liquid, pediatric heat-clearing and cough-relieving oral liquid, pediatric compound chicken gizzard chewable tablets, and Huperzine A tablets. The company serves hospitals, primary medical institutions, and retail terminals.
Henan Taloph Pharmaceutical Stock Co.,Ltd Fundamentals Summary
| 600222 fundamental statistics | |
|---|---|
| Market cap | CN¥3.02b |
| Earnings (TTM) | CN¥89.38m |
| Revenue (TTM) | CN¥1.97b |
33.8x
P/E Ratio1.5x
P/S RatioIs 600222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600222 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.97b |
| Cost of Revenue | CN¥1.42b |
| Gross Profit | CN¥551.71m |
| Other Expenses | CN¥462.33m |
| Earnings | CN¥89.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 28.04% |
| Net Profit Margin | 4.54% |
| Debt/Equity Ratio | 56.3% |
How did 600222 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield11%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 18:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Henan Taloph Pharmaceutical Stock Co.,Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Min Luo | Central China Securities Co., Ltd. |
| Wen Liang Cui | Founder Securities Co., Ltd. |
| Xiao Feng Wang | Shenwan Hongyuan Securities |